Literature DB >> 27114349

Integrative strategy for improving cancer immunotherapy.

Xuetao Cao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27114349     DOI： 10.1007/s00109-016-1424-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  11 in total

Review 1.  Adapting conventional cancer treatment for immunotherapy.

Authors:  Jian Qiao; Zhida Liu; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2016-02-24       Impact factor: 4.599

Review 2.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.

Authors:  Binfeng Lu; Min Yang; Qingqing Wang
Journal:  J Mol Med (Berl)       Date:  2016-02-27       Impact factor: 4.599

Review 3.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 4.  Macrophages and therapeutic resistance in cancer.

Authors:  Brian Ruffell; Lisa M Coussens
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

Review 6.  Immunosuppressive cells in tumor immune escape and metastasis.

Authors:  Yang Liu; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2015-12-22       Impact factor: 4.599

7.  IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.

Authors:  Ilona Kryczek; Yanwei Lin; Nisha Nagarsheth; Dongjun Peng; Lili Zhao; Ende Zhao; Linda Vatan; Wojciech Szeliga; Yali Dou; Scott Owens; Witold Zgodzinski; Marek Majewski; Grzegorz Wallner; Jingyuan Fang; Emina Huang; Weiping Zou
Journal:  Immunity       Date:  2014-05-08       Impact factor: 31.745

8.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

Authors:  Haidong Tang; Yang Wang; Lukasz K Chlewicki; Yuan Zhang; Jingya Guo; Wei Liang; Jieyi Wang; Xiaoxiao Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

9.  Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma.

Authors:  Jin Hou; Ye Zhou; Yuanyuan Zheng; Jia Fan; Weiping Zhou; Irene O L Ng; Huichuan Sun; Lunxiu Qin; Shuangjian Qiu; Joyce M F Lee; Chung-Mau Lo; Kwan Man; Yuan Yang; Yun Yang; Yingyun Yang; Qian Zhang; Xuhui Zhu; Nan Li; Zhengxin Wang; Guoshan Ding; Shi-Mei Zhuang; Limin Zheng; Xiaoling Luo; Yuan Xie; Anmin Liang; Zhugang Wang; Ming Zhang; Qiang Xia; Tingbo Liang; Yizhi Yu; Xuetao Cao
Journal:  Cancer Cell       Date:  2013-12-19       Impact factor: 31.743

10.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728
View more
  2 in total

1.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

Review 2.  Functions of Group 2 Innate Lymphoid Cells in Tumor Microenvironment.

Authors:  Jia Xiong; Haofei Wang; Jia He; Qingqing Wang
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.